We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03215004
Previous Study | Return to List | Next Study

Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03215004
Recruitment Status : Unknown
Verified September 2020 by American Gene Technologies International Inc..
Recruitment status was:  Recruiting
First Posted : July 12, 2017
Last Update Posted : September 16, 2020
Information provided by (Responsible Party):
American Gene Technologies International Inc.

Brief Summary:
Clinical specimens are required from HIV positive individuals with viremia controlled by antiretroviral therapy to complete process development for a genetically modified autologous T cell product, AGT103-T. The product will be used in a subsequent early stage clinical trial in subjects with chronic HIV disease and viremia suppressed by antiretroviral therapy as the initial step in testing a functional cure for HIV disease. Enrolled participants provide a venous blood specimen (approximately 25mL) to determine their level of HIV-reactive CD4+ T cells. Subjects with positive T cell responses will be asked to undergo leukapheresis and their clinical specimens will be used to validate and qualify the AGT103-T cell product.

Condition or disease
HIV Infections

Detailed Description:

This protocol is to collect blood specimens from HIV positive individuals. The first blood draw will be done at the first study visit and if eligible, the second blood collection will be done via leukapheresis at the second visit. The leukapheresis procedures will follow the facility's standard operating procedures and protocol requirements for leukapheresis.

Volunteers will be males or females between and including the ages of 18 years and 60 years. Volunteers will provide written informed consent and meet all inclusion and exclusion criteria. Each participant can be in the study for up to 120 days (3 months).

The study will be conducted in accordance with GCP/ICH for human research for the purposes of obtaining clinical specimens for research. There is no endpoint for this study, however, data collected from this study will include, but not be limited to, gender, demographics, medical history, clinical laboratory values, and volume of the blood collected. The data will be summarized in future studies reporting results from a planned clinical trial.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 24 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals
Actual Study Start Date : July 25, 2017
Estimated Primary Completion Date : February 7, 2021
Estimated Study Completion Date : February 7, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. Collection of clinical specimens [ Time Frame: up to 120 days ]
    The blood samples collected will be tested to measure the absolute and relative levels of CD4+ and CD8+ T cells. Data will describe the range of CD4+ T cell and CD8+ T cell responses to peptide stimulation. The samples will also help validate the assays and processes for the development of the cell product to be used in a future clinical trial.

Biospecimen Retention:   Samples With DNA
HIV positive samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with chronic, persistent HIV disease that is well-controlled by combination antiretroviral therapy

Inclusion Criteria:

  • Male or female aged between ≥18 and ≤60 years
  • Documented HIV infection for at least 3 years prior to study entry
  • Stable on HIV antiretroviral regimen with viral suppression to <50c/mL plasma for >2 years
  • Agrees not to change antiretroviral regimen (unless medically indicated) during the study period
  • CD4+ T cell count >500 cell per millimeter cubed (cells/mm3) at last measurement within 6 months of study participation
  • CD4+ T cell nadir of >350 cells/mm3
  • HIV plasma viral load <50 copies of viral RNA per milliliter (mL) for >2 years
  • Participants who had intermittent, isolated episodes of detectable low-level viremia (<500c/mL; blips) will remain eligible.
  • Have not received cytoreduction therapy within 3 months of study entry
  • Do not have prior events of hemorrhagic cystitis
  • Is not being treated or does not have bacteremia within the past 6 months
  • Does not have signs or symptoms of acute infectious disease
  • Adequate venous access and no other contraindications for leukapheresis
  • Hematocrit is >33% or hemoglobin is ≥13g/dL (males) and ≥12g/dL (females) at last measurement within 7 days prior to study enrollment; test also required within 3 days prior to leukapheresis
  • Weighs more than 75 lbs
  • Not pregnant at time of enrollment
  • Ability to understand the study and must be willing to comply with study-required procedures and visits, including only changing antiretroviral regimen when indicated by the study doctor during the study period
  • Written informed consent signed and dated by study participant

Exclusion Criteria:

  • Acute or chronic hepatitis B or hepatitis C infection with detectable viremia
  • Any viral hepatitis or liver disease (e.g. cirrhosis)
  • Active or recent (prior 6 months) AIDS defining complication
  • Any experimental HIV medications within the past 12 weeks
  • Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin
  • Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled angina or arrhythmias
  • Any clinically significant renal, hepatic, and pulmonary disease
  • Inadequate venous access or contraindicated for leukapheresis
  • Significant laboratory values and/or a chronic medical condition that, in the opinion of the Principal Investigator, could impact trial participation
  • Receiving another investigational drug or device within 30 days of study entry
  • Previously received any gene transfer therapy
  • History or any features on physical examination indicative of a bleeding diathesis
  • Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g. interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to screening (NOTE: Use of inhaled or topical steroids is not exclusionary)
  • Breast-feeding or pregnant
  • Use of aspirin, dipyridamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2-week period prior to leukapheresis
  • Active drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements
  • Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry
  • Recent vaccination or intercurrent illness within 5 weeks prior to T cell infusion (NOTE: It is recommended that participants should have completed their routine vaccinations, e.g. hepatitis A or B, pneumococcus, influenza and tetanus diphtheria booster, at least 30 days prior to screening for the study)
  • Asplenia: any conditions resulting in the absence of a functional spleen
  • History of hereditary angioedema, acquired angioedema or idiopathic angioedema

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03215004

Layout table for location information
United States, District of Columbia
Providence Hospital Completed
Washington, District of Columbia, United States, 20017
United States, Maryland
Institute of Human Virology, University of Maryland Baltimore Recruiting
Baltimore, Maryland, United States, 21201
Contact: Joyce Lam    410-706-3367    JLam@ihv.umaryland.edu   
Principal Investigator: Jennifer Husson, MD         
Sponsors and Collaborators
American Gene Technologies International Inc.
Layout table for additonal information
Responsible Party: American Gene Technologies International Inc.
ClinicalTrials.gov Identifier: NCT03215004    
Other Study ID Numbers: AGT-CS168
First Posted: July 12, 2017    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by American Gene Technologies International Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
HIV Seropositivity
Acquired Immunodeficiency Syndrome
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Genital Diseases
Urogenital Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases